stoxline Quote Chart Rank Option Currency Glossary
  
Regeneron Pharmaceuticals, Inc. (REGN)
969.91  3.42 (0.35%)    05-30 16:00
Open: 965.58
High: 971.86
Volume: 440,497
  
Pre. Close: 966.49
Low: 952.3
Market Cap: 105,106(M)
Technical analysis
2024-05-30 4:44:04 PM
Short term     
Mid term     
Targets 6-month :  1165.51 1-year :  1361.31
Resists First :  997.86 Second :  1165.51
Pivot price 978.13
Supports First :  922.07 Second :  875.22
MAs MA(5) :  975.02 MA(20) :  972.55
MA(100) :  948.64 MA(250) :  859.93
MACD MACD :  10.9 Signal :  12.8
%K %D K(14,3) :  38.6 D(3) :  51.2
RSI RSI(14): 53.8
52-week High :  998.33 Low :  684.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ REGN ] has closed above bottom band by 23.9%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 973.25 - 978.7 978.7 - 983.69
Low: 937.8 - 944.99 944.99 - 951.57
Close: 959.46 - 969.92 969.92 - 979.48
Company Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Headline News

Thu, 30 May 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron ... - PR Newswire

Thu, 30 May 2024
Congress Wealth Management LLC DE Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World

Thu, 30 May 2024
Orion Portfolio Solutions LLC Sells 12934 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World

Wed, 29 May 2024
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Wed, 29 May 2024
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Wed, 29 May 2024
D.A. Davidson & CO. Buys 103 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 108 (M)
Shares Float 103 (M)
Held by Insiders 1.6 (%)
Held by Institutions 89.6 (%)
Shares Short 1,570 (K)
Shares Short P.Month 1,420 (K)
Stock Financials
EPS 33.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 250.14
Profit Margin 29.4 %
Operating Margin 24.1 %
Return on Assets (ttm) 7.7 %
Return on Equity (ttm) 15.2 %
Qtrly Rev. Growth -0.5 %
Gross Profit (p.s.) 0
Sales Per Share 120.88
EBITDA (p.s.) 40.78
Qtrly Earnings Growth -12.7 %
Operating Cash Flow 4,740 (M)
Levered Free Cash Flow 3,030 (M)
Stock Valuations
PE Ratio 28.61
PEG Ratio 2.2
Price to Book value 3.87
Price to Sales 8.02
Price to Cash Flow 22.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android